Piper Sandler Issues Neutral Ratings for Agilent, Danaher, and WAT

Piper Sandler initiated research coverage on three life-science tools names, assigning Neutral ratings to Agilent A, Danaher DHR and Waters WAT. The firm set a $200 price target on Danaher, calling it the 'highest quality compounder' in the life-science tools sector while signaling balanced risk/reward at current levels; Waters was assigned a target near $400.

The coverage coincides with Danaher's completed acquisition of Masimo, finalized June 10 at $180 per share, which folds Masimo's patient-monitoring technology into Danaher's diagnostics portfolio. The deal expands Danaher's healthcare exposure as it leans on the Danaher Business System to integrate the asset.

Neutral initiations across the group suggest analysts see fair valuations rather than clear upside catalysts in life-science tools near term. Investors will watch post-deal integration at Danaher and whether sector demand reaccelerates enough to justify a re-rating.